Cargando…

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans

The four-dengue virus (DENV) serotypes infect several hundred million people annually. For the greatest safety and efficacy, tetravalent DENV vaccines are designed to stimulate balanced protective immunity to all four serotypes. However, this has been difficult to achieve. Clinical trials with a lea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nivarthi, Usha K., Swanstrom, Jesica, Delacruz, Matthew J., Patel, Bhumi, Durbin, Anna P., Whitehead, Steve S., Kirkpatrick, Beth D., Pierce, Kristen K., Diehl, Sean A., Katzelnick, Leah, Baric, Ralph S., de Silva, Aravinda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889627/ https://www.ncbi.nlm.nih.gov/pubmed/33597521 http://dx.doi.org/10.1038/s41467-021-21384-0

Ejemplares similares

Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model
por: Nivarthi, Usha K., et al.
Publicado: (2019)

Corrigendum to ‘‘Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model’’ [EBioMedicine 41 (2019) 465–478]
por: Nivarthi, Usha K., et al.
Publicado: (2020)

Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines
por: Swanstrom, Jesica A, et al.
Publicado: (2019)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4
por: Widman, Douglas G., et al.
Publicado: (2017)

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
por: Martinez, David R., et al.
Publicado: (2020)

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization
por: Gallichotte, Emily N., et al.
Publicado: (2018)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes
por: Gallichotte, Emily N., et al.
Publicado: (2018)

Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas
por: Andrade, Daniela V., et al.
Publicado: (2019)

Dengue genetic divergence generates within-serotype antigenic variation, but serotypes dominate evolutionary dynamics
por: Bell, Sidney M, et al.
Publicado: (2019)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
por: Whitehead, Stephen S., et al.
Publicado: (2017)

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes
por: Andrade, Daniela V., et al.
Publicado: (2017)

Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model
por: Hanley, John P., et al.
Publicado: (2021)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses
por: Wahala, Wahala M. P. B., et al.
Publicado: (2010)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
por: Metz, Stefan W., et al.
Publicado: (2018)

Rapid Induction and Maintenance of Virus-Specific CD8(+) T(EMRA) and CD4(+) T(EM) Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans
por: Graham, Nancy, et al.
Publicado: (2020)

Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone
por: Gallichotte, Emily N., et al.
Publicado: (2017)

Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization
por: Messer, William B., et al.
Publicado: (2012)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera
por: de Alwis, Ruklanthi, et al.
Publicado: (2014)

Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2
por: Zhu, Deanna R., et al.
Publicado: (2023)

A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies
por: Gallichotte, E. N., et al.
Publicado: (2015)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

‘Mix and Match’ vaccination: Is dengue next?
por: Odio, Camila D., et al.
Publicado: (2022)

Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation()
por: Bentsi-Enchill, Adwoa D., et al.
Publicado: (2013)

Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine
por: Lin, Tsung-Han, et al.
Publicado: (2020)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus
por: Katzelnick, Leah C., et al.
Publicado: (2018)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Plant‐expressed Fc‐fusion protein tetravalent dengue vaccine with inherent adjuvant properties
por: Kim, Mi Young, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_si1v50pdq108567c69mho75ikd